北京海润天睿律师事务所 法律意见书 致：九州通医药集团股份有限公司 关于九州通医药集团股份有限公司差异化分红事项的 法律意见书 中国·北京 朝阳区建外大街甲14号广播大厦5层、9层、10层、13层、17层 邮政编码：100022 电话：010-65219696 传真：010-88381869 二〇二五年五月 北京海润天睿律师事务所 关于九州通医药集团股份有限公司差异化分红事项的 北京海润天睿律师事务所（以下简称"本所"）接受九州通医药集团股份有 限公司（以下简称"公司"）委托，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券 监督管理委员会（以下简称"中国证监会"）发布的《上市公司股份回购规则》 （以下简称《回购规则》）、上海证券交易所发布的《上海证券交易所上市公司 自律监管指引第 7 号——回购股份》（以下简称"《自律指引 7 号》"）等法律、 法规和规范性文件的规定，以及《九州通医药集团股份有限公司章程》（以下简 称《公司章程》）的规定，就公司 2024 年度利润分配涉及的差异化分红特殊除 权除息处理（以下简称"本次差异化分红"）相关事项出具本 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-043 本次利润分配方案经九州通医药集团股份有限公司（以下简称"公司"）2025 年 5 月 23 日 的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 九州通医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.20元（含税） ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/16 | － | 2025/6/17 | 2025/6/17 | | ? 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，上市 公 ...

Group 1 - The stock price of Haiwang Bio has broken through the top of a six-month trading range, with a cumulative increase of 8.97% over nine trading days, significantly outperforming the industry average of 3.36% [1][2] - The trading volume reached 664.55 million shares, with a total capital inflow of 1.71 billion yuan, indicating a notable increase in trading activity [1][2] Group 2 - Despite facing significant cyclical pressures in recent years, Haiwang Bio's revenue for 2024 is expected to maintain a substantial level of 30.317 billion yuan, driven by strategic adjustments and optimization of low-efficiency subsidiaries [4] - The company anticipates a net loss attributable to shareholders of 1.193 billion yuan for 2024, which represents a significant reduction compared to the previous year's loss of 1.69 billion yuan [4] - The company has been actively reducing goodwill impairment, which is nearing completion, laying a foundation for long-term growth [4] Group 3 - The Chinese pharmaceutical industry is undergoing a critical phase of quality upgrades, with policies accelerating the exit of small distributors, benefiting leading companies like Haiwang Bio [6] - Haiwang Bio is enhancing its competitive edge through a nationwide logistics network and is transitioning from product provision to service solutions, including customized SPD services for medical institutions [6] - The company has received clinical trial approval for its self-developed NEP018 tablet, a small molecule enzyme inhibitor targeting gastrointestinal tumors, which is expected to open a new growth avenue as the market for small molecule anti-tumor drugs is projected to exceed 200 billion yuan by 2030 [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 2025年6月，北京市竞天公诚律师事务所上海分所就南京医药股份有限公司2021年限制性股票激励计划 回购注销部分限制性股票实施情况出具法律意见书。 已履行必要程序并完成信息披露 回购注销具体情况原因及依据：依据《激励计划》，因28名激励对象分别因离职、退休、考核不达标等 不符合激励条件，公司需对其已获授但尚未解除限售的409,626股限制性股票进行回购注销。对象及股 份数量：涉及核心骨干（非董事、高级管理人员）28人，合计拟回购注销限制性股票409,626股，即 40.96万股。注销日期：公司已在中登上海分公司开设回购专用证券账户，并申请办理回购注销手续， 上述限制性股票预计于2025年6月12日完成注销，后续将依法办理股份注销登记等手续。 律师认为，截至法律意见书出具之日，南京医药本次回购注销符合注销条件，涉及对象、股份数量及注 销日期均符合相关规定。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第 ...

上交所公开信息显示，当日该股因日振幅值达16.59%上榜，营业部席位合计净卖出38.44万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.71亿元，其中，买入成交额为8547.13 万元，卖出成交额为8585.57万元，合计净卖出38.44万元。 人民同泰(600829)今日下跌4.65%，全天换手率11.24%，成交额5.99亿元，振幅16.59%。龙虎榜数据显 示，营业部席位合计净卖出38.44万元。 具体来看，今日上榜营业部中，第一大买入营业部为国新证券股份有限公司北京中关村大街证券营业 部，买入金额为2592.48万元，第一大卖出营业部为开源证券股份有限公司湖北分公司，卖出金额为 2921.16万元。 | 卖四 | 中泰证券股份有限公司北京朝外大街证券营业部 | 1307.60 | | --- | --- | --- | | 卖五 | 申万宏源证券有限公司上海静安区延长中路证券营业部 | 1130.24 | （文章来源：证券时报网） 4月19日公司发布的一季报数据显示，一季度公司共实现营业收入26.67亿元，同比增长2.65%，实现净 利润4584.09万元，同比下降41.48%。（ ...

中国经济网北京6月9日讯 海王生物（000078）（000078.SZ）6月7日发布关于终止控制权变更及向特定 对象发行股票事项的公告。近日，公司、海王集团及丝纺集团签署了《<关于深圳市海王生物工程股份 有限公司之合作协议书>解除协议》，丝纺集团与海王集团及其一致行动人张思民、张锋、王菲签署了 《<关于深圳市海王生物工程股份有限公司之股份转让协议>及<关于深圳市海王生物工程股份有限公司 之表决权放弃协议>解除协议》，公司本次控制权变更事项终止。 鉴于公司控制权变更事项终止，公司于2025年6月6日召开了2025年第三次独立董事专门会议、第九届董 事局第二十四次会议、第九届监事会第二十次会议，审议通过了终止向特定对象发行A股股票事项的相 关事项，同意终止向特定对象发行A股股票，并签署股份认购协议的解除协议。 海王生物2024年7月30日披露《2024年度向特定对象发行A股股票预案》称，本次向特定对象发行A股股 票的发行对象为丝纺集团及其控股股东广新集团。丝纺集团、广新集团拟以现金方式认购公司本次发行 的全部股票。 丝纺集团取得上市公司控制权后，按照拟发行股数计算，本次发行完成后，丝纺集团及其一致行动人持 有的上 ...

Core Viewpoint - 九州通 is undergoing a strategic transformation towards light asset operations and aims to become a dual-listed company on A-shares and public REITs, enhancing its market position in the biopharmaceutical industry [1][2]. Group 1: Strategic Transformation - 九州通 is focusing on a "three new and two modernization" strategy in 2024, achieving significant results in new products, new retail, new medical services, digitalization, and real estate securitization [2]. - The company has established a multi-level real estate equity capital operation platform, marking its transition from heavy assets to light assets [3]. Group 2: Financial Performance - In 2024, 九州通's total revenue reached 151.81 billion yuan, a year-on-year increase of 2.58%, while net profit attributable to shareholders was 2.507 billion yuan, up 39.88% [2]. - In Q1 2025, the company reported revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth [2]. Group 3: Product Pipeline Expansion - 九州通's product pipeline is expanding with the approval of "Betamethasone Sodium Phosphate Injection," which is expected to enhance market share and strengthen the company's competitive position in the injection product market [1][4]. - The company achieved sales revenue of 3.007 billion yuan from its self-produced and OEM pharmaceutical business in 2024, marking a 21.49% increase [5]. Group 4: Research and Development - 九州通's R&D investment in 2024 was 346 million yuan, reflecting a year-on-year growth of 24.32% [2].

Core Viewpoint - Haiwang Bio announced the termination of its nearly three-year plan to change its controlling rights, marking a pause in its efforts to introduce state-owned capital from Guangdong Province [1][4] Financial Performance - As of June 6, Haiwang Bio's stock price closed at 2.56 yuan per share, with a year-to-date increase of only 0.39%, resulting in a total market capitalization of 6.736 billion yuan [3] - The company has reported continuous losses for three consecutive years, with cumulative losses exceeding 3.7 billion yuan from 2022 to 2024. The first quarter of 2025 showed a 44.38% year-on-year decline in net profit to 23.72 million yuan, with an actual loss of 74.74 million yuan after excluding non-recurring gains and losses [4][6] Financial Structure - As of March 2025, the company's debt-to-asset ratio rose to 89.76%, significantly higher than the industry average in pharmaceutical distribution. Short-term debt reached 13.043 billion yuan, while cash and cash equivalents were only 4.565 billion yuan, indicating ongoing pressure on short-term debt repayment capabilities [6] - Accounts receivable reached 15.367 billion yuan, exceeding 200% of the current operating revenue, leading to tight operating capital and high collection risks due to long-term occupation of funds by hospital clients [6] Future Development and Restructuring - In the first half of 2024, the company faced 109 lawsuits related to accounts receivable, with a total amount exceeding 535 million yuan. The company recorded goodwill impairment of over 800 million yuan in 2023 and expects to continue impairing between 400 million to 570 million yuan in 2024, maintaining a goodwill balance of 863 million yuan by year-end [7] - The company plans to focus on resource integration and market expansion in the medical device sector, aiming to optimize its industrial layout and deepen strategic cooperation for business transformation and upgrading [8]

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Viewpoint - The company has decided to terminate its plan for a specific issuance of A-shares for 2024 after discussions with strategic investors, indicating a strategic adjustment in its operations [1][2]. Group 1: Termination of A-share Issuance - The termination of the A-share issuance will not have a substantial impact on the company's normal operations or harm shareholder interests [1]. - The decision was made after friendly consultations with Shenzhen Haiwang Group Co., Ltd. and Guangdong Silk Textile Group Co., Ltd. [1]. Group 2: Business Strategy and Performance - The company has been focusing on restructuring its business, particularly in the medical device sector, while divesting non-core and underperforming assets to enhance operational efficiency [1][2]. - In 2024, the company achieved a revenue of 30.317 billion yuan, maintaining steady growth despite a complex market environment [1]. - The company has completed goodwill impairment provisions, laying a solid foundation for future development [1]. Group 3: Medical Device Business - The company has established a comprehensive supply chain network covering over 20 provinces and cities in China, maintaining long-term stable partnerships with international brands like Siemens and Mindray Medical [2]. - Future plans include expanding the scale of its medical device agency business and deepening strategic cooperation with high-quality domestic and international suppliers [2]. Group 4: Financial Management and Outlook - As of the end of 2024, the company's goodwill was valued at approximately 379 million yuan, allowing it to focus on high-value-added business areas [2]. - The company has successfully completed equity transfers of several subsidiaries, optimizing its asset structure and supporting its transformation [2]. - Although facing short-term financial pressures, the effective release of goodwill risks and the strengthening of core businesses are expected to improve the company's operational status and create sustainable value for investors [2].